Related Experiment Video
Updated: Feb 23, 2026

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
Published on: September 28, 2015
Angiotensin II type 1a receptor-deficient mice develop angiotensin II-induced oxidative stress and DNA damage without
Anna Zimnol1, Kerstin Amann2, Philipp Mandel1
1Institute of Toxicology, Medical Faculty, University of Düsseldorf, Düsseldorf, Germany; and.
Abstract:
Hypertensive patients have an increased risk of developing kidney cancer. We have shown in vivo that besides elevating blood pressure, angiotensin II causes DNA damage dose dependently. Here, the role of blood pressure in the formation of DNA damage is studied. Mice lacking one of the two murine angiotensin II type 1 receptor (AT1R) subtypes, AT1aR, were equipped with osmotic minipumps, delivering angiotensin II during 28 days. Parameters of oxidative stress and DNA damage of kidneys and hearts of AT1aR-knockout mice were compared with wild-type (C57BL/6) mice receiving angiotensin II, and additionally, with wild-type mice treated with candesartan, an antagonist of both AT1R subtypes. In wild-type mice, angiotensin II induced hypertension, reduced kidney function, and led to a significant formation of reactive oxygen species (ROS). Furthermore, genomic damage was markedly increased in this group. All these responses to angiotensin II could be attenuated by concurrent administration of candesartan. In AT1aR-deficient mice treated with angiotensin II, systolic pressure was not increased, and renal function was not affected. However, angiotensin II still led to an increase of ROS in kidneys and hearts of these animals. Additionally, genomic damage in the form of double-strand breaks was significantly induced in kidneys of AT1aR-deficient mice. Our results show that angiotensin II induced ROS production and DNA damage even without the presence of AT1aR and independently of blood pressure changes.
Insights
Angiotensin II causes DNA damage and reactive oxygen species (ROS) production, even without increasing blood pressure. This study investigates the role of blood pressure in angiotensin II-induced genomic damage.
Area of Science:
- Cardiovascular Research
- Nephrology
- Molecular Biology
Background:
- Hypertension is linked to increased kidney cancer risk.
- Angiotensin II is known to elevate blood pressure and cause DNA damage.
- The specific role of blood pressure in this damage requires further elucidation.
Purpose of the Study:
- To investigate the role of blood pressure in angiotensin II-induced DNA damage.
- To differentiate the effects of angiotensin II on oxidative stress and DNA damage independent of hypertension.
- To examine the involvement of angiotensin II type 1 receptor (AT1R) subtypes in these processes.
Main Methods:
- Utilized AT1aR-knockout mice and wild-type mice treated with angiotensin II.
- Administered angiotensin II via osmotic minipumps for 28 days.
- Assessed parameters of oxidative stress, DNA damage (including double-strand breaks), blood pressure, and kidney function.
Main Results:
- In wild-type mice, angiotensin II caused hypertension, reduced kidney function, increased reactive oxygen species (ROS), and genomic damage.
- Candesartan treatment attenuated these angiotensin II effects in wild-type mice.
- In AT1aR-knockout mice, angiotensin II increased ROS and induced genomic double-strand breaks without affecting blood pressure or kidney function.
Conclusions:
- Angiotensin II induces ROS production and DNA damage independently of blood pressure elevation.
- The AT1aR subtype is not essential for angiotensin II-induced ROS production and DNA damage.
- These findings highlight a direct mechanism of angiotensin II in causing cellular damage relevant to kidney disease and cancer risk.
Related Concept Videos
Hypertension II: Pathophysiology
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Drugs: Direct Renin Inhibitors
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Action of β1 Blockers

